Kura Oncology, Inc. announced that on June 7, 2018, Heidi Henson notified the company of her intention to resign from her position as Chief Financial Officer and Secretary, to pursue other opportunities. She will remain with the company as its Chief Financial Officer and Secretary through July 6, 2018. Ms. Henson has agreed to serve as a consultant to the company following her resignation to assist with the transition, under the terms of a consulting agreement entered into with the company on June 8, 2018 that will become effective upon Ms. Henson's resignation.

Upon Ms. Henson's resignation, in the interim, Troy E. Wilson, the company's President and Chief Executive Officer, will act as the company's principal financial officer and principal accounting officer for purposes of the Securities Exchange Act of 1934.